Ocugen, Inc. (OCGN)
Stock Price:
$0.320 USD
0.005 (1.59%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $0.317 -0.003 (-0.91%) Oct 22, 7:57 PM
Key Info
| Market Cap |
51.85M |
| Revenue (ttm) |
42,620 |
| Net Income (ttm) |
-17.95M |
| Shares Out |
135.01M |
| EPS (ttm) |
0.32 |
| PE Ratio |
1.00 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$0.320 |
| Previous Close |
$0.315 |
| Change ($) |
0.005 |
| Change (%) |
1.59% |
| Day's Open |
0.320 |
| Day's Range |
0.312 - 0.327 |
| Day's Volume |
2,637,825 |
| 52-Week Range |
0.170 - 2.050 |
More Stats
| Market Cap |
51.85M |
| Enterprise Value |
43.07M |
| Earnings Date (est) |
Nov 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
135.01M |
| Float |
155.65M |
| EPS (basic) |
0.32 |
| EPS (diluted) |
0.32 |
| FCF / Share |
-0.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
100.00% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.11M |
| Short Ratio |
0.63 |
| Short % of Float |
3.92% |
| Beta |
n/a |
| PE Ratio |
1.00 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,216.53 |
| PB Ratio |
3.00 |
| Revenue |
42,620 |
| Operating Income |
-14.29M |
| Net Income |
-17.95M |
| Free Cash Flow |
-13.29M |
| Net Cash |
8.78M |
| Net Cash / Share |
0.05 |
| Gross Margin |
100.00% |
| Operating Margin |
-33,525.15% |
| Profit Margin |
-71,551.70% |
| FCF Margin |
-31,184.40% |
| ROA |
-60.93% |
| ROE |
-421.47% |
| ROIC |
1,594.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$0.85*
(165.63% upside)
Low
0.70
Current: $0.320
High
1.00
Target: 0.85
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | 0.03 |
| Gross Profit | - | - | - | - | - | - | - | 0.03 |
| Operating Income | -14.16 | -16.14 | -24.95 | -30.31 | -31.82 | -32.66 | -16.85 | -14.97 |
| Net Income | -20.24 | -18.22 | -22.50 | -13.86 | -32.02 | -10.51 | -56.00 | 2.81 |
| Shares Outstanding | 13.89 | 4.96 | 0.38 | 0.24 | 0.22 | 0.03 | 0.01 | - |
| Earnings Per Share | -1.46 | -3.67 | -59.39 | -130.77 | -145.17 | -410.92 | -5,793.64 | 170.97 |
| Operating Cash Flow | -16.89 | -11.63 | -23.02 | -25.74 | -30.03 | -17.94 | -15.28 | -12.23 |
| Capital Expenditures | -0.03 | -0.08 | -0.28 | -0.32 | -1.95 | -3.32 | -0.55 | -0.08 |
| Free Cash Flow | -16.92 | -11.71 | -23.30 | -26.06 | -31.98 | -21.26 | -15.84 | -12.31 |
| Cash & Equivalents | 7.60 | 1.78 | 8.12 | 32.05 | 31.05 | 58.66 | 9.26 | 15.24 |
| Total Debt | 1.41 | 8.50 | 0.18 | 0.76 | 1.34 | 1.75 | - | - |
| Net Cash / Debt | 6.19 | -6.72 | 7.94 | 31.28 | 29.71 | 56.91 | 9.26 | 15.24 |
| Assets | 16.81 | 2.45 | 11.04 | 36.08 | 36.79 | 65.50 | 14.80 | 21.04 |
| Liabilities | 5.79 | 15.16 | 22.30 | 22.51 | 8.59 | 11.29 | 33.28 | 11.14 |
| Book Value | 11.02 | -12.71 | -11.27 | 13.57 | 28.20 | 54.21 | -75.55 | -19.71 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ocugen, Inc. |
| Country |
United States |
| Employees |
16 |
| CEO |
Shankar Musunuri |
Stock Information
| Ticker Symbol |
OCGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OCGN |
Description
Ocugen, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.